Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stan Kaye

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Future Oncology (London, England)|June 22, 2006
Which drugs for which patients?Stan Kaye
Current Oncology Reports|September 14, 2011
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyondSusana Banerjee, Stan Kaye
Onkologie|November 15, 2005
[Value of inhibition of signal transduction and epigenetic therapy concepts in cancer therapy]Josep Tabernero, Stan Kaye
Current Oncology Reports|September 5, 2012
Progression-free survival versus overall survival in ovarian cancer: where are we now?Susana Banerjee, Stan Kaye
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
The role of targeted therapy in ovarian cancerSusana Banerjee, Stan Kaye
Journal of Clinical Pathology|October 5, 2006
Ovarian clear cell adenocarcinoma: a continuing enigmaDavid S P Tan, Stan Kaye
Oncotarget|June 15, 2017
Olaparib and somatic BRCA mutationsAngela George, Susana Banerjee, Stan Kaye
Nature Reviews. Clinical Oncology|December 14, 2016
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancerAngela George, Stan Kaye, Susana Banerjee
Current Drug Targets|September 15, 2012
Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trialsJoo Ern Ang, Stan Kaye, Udai Banerji
Pathologie-Biologie|March 21, 2006
Update on tubulin-binding agentsGerhardt Attard, Alastair Greystoke, Stan Kaye, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Future Oncology (London, England)|June 22, 2006
Which drugs for which patients?Stan Kaye
Current Oncology Reports|September 14, 2011
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyondSusana Banerjee, Stan Kaye
Onkologie|November 15, 2005
[Value of inhibition of signal transduction and epigenetic therapy concepts in cancer therapy]Josep Tabernero, Stan Kaye
Current Oncology Reports|September 5, 2012
Progression-free survival versus overall survival in ovarian cancer: where are we now?Susana Banerjee, Stan Kaye
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
The role of targeted therapy in ovarian cancerSusana Banerjee, Stan Kaye
Journal of Clinical Pathology|October 5, 2006
Ovarian clear cell adenocarcinoma: a continuing enigmaDavid S P Tan, Stan Kaye
Oncotarget|June 15, 2017
Olaparib and somatic BRCA mutationsAngela George, Susana Banerjee, Stan Kaye
Nature Reviews. Clinical Oncology|December 14, 2016
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancerAngela George, Stan Kaye, Susana Banerjee
Current Drug Targets|September 15, 2012
Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trialsJoo Ern Ang, Stan Kaye, Udai Banerji
Pathologie-Biologie|March 21, 2006
Update on tubulin-binding agentsGerhardt Attard, Alastair Greystoke, Stan Kaye, et al.
Pageof 5